Effective Sensitizing Dose of a Gelled Immunomodulating Topical Composition
a topical composition and gel technology, applied in the direction of biocide, drug composition, antibody medical ingredients, etc., can solve the problems of high recurrence rate, cancerous cell recurrence, and difficult management of in-transit disease, so as to reduce tumor growth rate, reduce tumor mass, and eliminate residual disease
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Benefits of technology
Problems solved by technology
Method used
Examples
experimental examples
[0157]The invention is further described in detail by reference to the following experimental examples. These examples are provided for purposes of illustration only, and are not intended to be limiting unless otherwise specified. Thus, the invention should in no way be construed as being limited to the following examples, but rather, should be construed to encompass any and all variations which become evident as a result of the teaching provided herein.
example 1
Low Dose Sensitization of DPCP for the Treatment of Warts
[0158]Patients were initially sensitized with 0.4% DPCP gel at the primary wart site. Approximately 14 days later and weekly thereafter for various periods, a challenge dose is then applied. A challenge dose of 0.04% DPCP was employed. The DPCP used was incorporated in a unique blend of surfactants, a viscosity agent, and a preservative. See Table 1 and 2.
TABLE 10.4% DPCP sensitizing dose%1000 gram batchDiphenylcyclopropenone0.404.0Butylated hydroxytoluene NF0.020.2Polysorbate 80 NF49.79497.9Isopropyl myristate NF49.79497.9
TABLE 20.04% DPCP challenge dose%1000 gram batchDiphenylcyclopropenone0.0400.40Butylated hydroxytoluene NF0.010.10Polysorbate 80 NF49.975499.75Isopropyl myristate NF49.975499.75
[0159]It was observed that the treatment regimen of 0.4% DPCP sensitizing dose in combination with a challenge dose of 0.04% DPCP exhibited at least two benefits. First, the treatment regimen using a low sensitizing dose of 0.04% DPCP...
example 2
Low Dose Sensitization of DPCP for the Treatment of Verruca Conditions
[0178]Institutional review board approval was obtained for this study, which was performed using Good Clinical Practice Guidelines and was compliant with the Code of Federal Regulation of the US Food and Drug Administration. A single center, 24 subject, randomized, double-blind, placebo control study using low dose DPCP in a non-volatile vehicle for the treatment of non-genital warts of established.
[0179]Patients are assigned to a treatment or placebo group in a 2:1 fashion. The two study gels are identical in appearance. Both groups are sensitized with 0.1 ml of 0.4% DPCP gel which is applied to the inner arm and washed off in 24 hours. Fourteen days after the sensitization dose, 0.1 ml of 0.04% DPCP gel or placebo is applied to each wart, up to a total of 4 warts, twice a week for 7 consecutive weeks (Day 14, 21, 28, 35, 42, 49, 56, 63). A final follow-up examination is performed on day 77. Patients are assessed...
PUM
Property | Measurement | Unit |
---|---|---|
Fraction | aaaaa | aaaaa |
Fraction | aaaaa | aaaaa |
Fraction | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com